Sensorion appoints Fred Chereau as CEO as gene therapy programs advance
PARIS: Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, said Tuesday that Fred Chereau will become chief executive officer effective June 1, 2026, as the company prepares for pivotal clinical milestones in its gene therapy pipeline. Chereau brings more than 30 years of leadership experience across biotechnology, pharmaceutical and medical device industries, with expertise…